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Neonatal Encephalopathy
Neonatal encephalopathy due to hypoxia-ischemia occurs in 1 to 6 per 1,000 live term births in developed countries. Approximately 15% to 20% of affected newborns die in the postnatal period, and an additional 25% sustain childhood disabilities. Abnormal findings on the neurologic examination in first few days after birth is the single most useful predictor in childhood that a brain insult has occurred in the perinatal period. Neonates who have mild encephalopathy do not have an increased risk of motor or cognitive deficits. Those who have severe encephalopathy have an increased risk of death and an increased risk of cerebral palsy and intellectual disability among survivors. Neonates who have moderate encephalopathy have significant motor deficits, memory impairment, and visual motor or visual perceptive dysfunction; increased hyperactivity; and delayed school readiness. (1)(2) The essential criteria suggested as prerequisites for a diagnosis of a hypoxic-ischemic insult resulting in moderate or severe encephalopathy in term newborns include: metabolic acidosis, with a cord pH less than 7 or a base deficit of at least 12 mmol/L; early onset of encephalopathy; multisystem organ dysfunction; and exclusion of other causes such as trauma, coagulation disorders, metabolic disorders, and genetic causes. (3)
Pathophysiology of Neonatal Hypoxic-Ischemic Brain Injury
The pathophysiology of brain injury due to hypoxia-ischemia has been well studied. Hypoxia-ischemia is associated with two phases of pathologic events that culminate in brain injury (Table 1) . These phases of primary and secondary energy failure are based on characteristics of the cerebral energy state used to describe the temporal sequence in newborn animals. (4) Primary energy failure is characterized by reductions in cerebral blood flow and oxygen/substrates. (4)(5) Concentrations of high-energy phosphorylated compounds such as adenosine triphosphate (ATP) and phosphocreatine are reduced and tissue acidosis is prominent. This phase is an essential prerequisite for all deleterious events that follow. Primary energy failure is associated with acute intracellular derangements such as loss of membrane ionic homeostasis, release/blocked reuptake of excitatory neurotransmitters, defective osmoregulation, and inhibition of protein synthesis. (6) Excessive stimulation of neurotransmitter receptors and loss of ionic homeostasis mediate an increase in intracellular calcium and osmotic dysregulation. Elevation in intracellular calcium concentrations triggers a number of destructive pathways by activating lipases, proteases, and endonucleases. (7) Resolution of hypoxia-ischemia within a specific time interval reverses the decrease in highenergy phosphorylated metabolites and intracellular pH and promotes recycling of neurotransmitters. The duration of time required for reversal of hypoxia-ischemia and promotion of recovery is affected by maturation, preconditioning events, substrate availability, body temperature, and simultaneous disease processes.
Although the cerebral energy state may recover following primary energy failure, a second interval of energy failure may occur at a time remote from the initiating event. Secondary energy failure differs from primary energy failure in that declines in phosphocreatine and ATP are not accompanied by brain acidosis. (4) The presence and severity of secondary energy failure depends on the extent of primary energy failure.
The pathogenesis of secondary energy failure is not as well understood as primary energy failure but likely involves multiple pathophysiologic processes, including accumulation of excitatory neurotransmitters, oxidative injury, apoptosis, inflammation, and altered growth factors and protein synthesis. (8)(9)(10)(11) (12) The interval between primary and secondary energy failure represents a latent phase that corresponds to a therapeutic window. Initiation of therapies during the latent phase in perinatal animals has been successful in reducing brain damage and substantiates the presence of a therapeutic window. The duration of the therapeutic window is approximately 6 hours in near-term fetal sheep, based on the neuroprotection associated with brain cooling initiated at varying intervals following brain ischemia. (13)(14)(15)
Current Therapies for Neonatal HypoxicIschemic Encephalopathy
The management of hypoxic-ischemic encephalopathy (HIE) has been limited to supportive intensive care. Such measures include correction of hemodynamic and pulmonary disturbances (hypotension, metabolic acidosis, and hypoventilation), correction of metabolic disturbances (glucose, calcium, magnesium, and electrolytes), treatment of seizures, and monitoring for other organ system dysfunction. This management approach does not target any component of the pathophysiologic sequence leading to hypoxic-ischemic brain injury and is directed at avoiding injury from secondary events associated with hypoxia-ischemia.
Diagnosis of Encephalopathy in Term Infants
A detailed history should be obtained regarding the pregnancy and intrapartum period as the first step in diagnosing encephalopathy. Any event likely to compromise blood or oxygen supply to the fetus should be examined. These events include a history of placental abruption, uterine rupture, amniotic fluid embolism, tight nuchal cord, cord prolapse/avulsion, maternal hemorrhage, trauma or cardiorespiratory arrest, severe and sustained fetal bradycardia, and prolonged labor. Most infants who have encephalopathy do not have an obvious cause. There is currently no clear diagnostic test for encephalopathy due to hypoxia-ischemia. A history of maternal elevation of temperature is crucial because moderate temperature elevation in the mother increases the risk of neonatal encephalopathy. A history of fetal tachycardia and maternal tachycardia also may raise suspicions of chorioamnionitis. Laboratory evaluations that should be performed include placenta pathology to eval- 
Hypothermia as Neuroprotection
Neuroprotection with brain-specific therapies has been well studied in the preclinical arena over the past 20 years, with the aim of blocking or dampening the cascade of events triggered by hypoxia and ischemia. Brain hypothermia is a promising therapy for neuroprotection against encephalopathy presumably due to hypoxic ischemia.
Preclinical Studies
Established evidence in fetal and neonatal animal models and across species shows that cooling by a depth of 4.0°C to 6.0°C compared with controls has been neuroprotective while being well tolerated. (13) The mechanism of protection has been documented by many modalities, including a decrease in brain energy utilization measured by magnetic resonance spectroscopy, (32) reduction of infarct size, (33) decrease in neuronal cell loss, (14) retention of sensory motor function, (19) preservation of hippocampal structures, (21)(22) and recovery of electroencephalographic activity (14) ( Table 2 ). Neuroprotection with hypothermia is temperature-specific, with progressively increased protection associated with increasing depth of temperature. Covey and Oorschot (34) noted that hypothermia of 5.0°C below normal administered postinsult for 6 hours offered better neuroprotection for striatal neurons than a depth of 2.0°C below normal. Iwata and colleagues (35) have demonstrated that cooling at two different regimens (rectal temperatures of 35.0°C and 33.0°C compared with normothermia of 38.5°C to 39.0°C) for 48 hours resulted in a progressive increase in neuronal viability in gray matter at 33.0°C compared with 35.0°C. Laptook and colleagues (32) noted a linear relationship between brain energy utilization rate and brain temperature over the range of temperatures between 27.6°C and 41°C, with a 1°C reduction in brain temperature leading to 5.3% reduction in brain energy utilization rate. Taylor and coworkers (33) evaluated infarct size with cooling to 33.0°C and 30.0°C compared with normothermia and found smaller infarct size at both depths compared with normothermia. Williams and associates (36) have evaluated cerebral energy metabolism during hypoxia-ischemia and demonstrated that when compared with controls, nuclear magnetic resonance metabolites were preserved at 31.0°C and 34.0°C. None of these studies comparing different depths of temperature 
Clinical Studies
To date, two randomized, controlled trials and one large pilot study have been published evaluating hypothermia as neuroprotection for term and near-term infants who have HIE. The multicenter Cool Cap Study involved 243 infants who had moderate or severe encephalopathy and abnormal aEEG amplitudes and were either cooled to a temperature of 34.0°C to 35.0°C for 72 hours or treated with temperature maintenance in the normothermia range with conventional care. (37) The primary outcome of the study was death or disability at 18 months. Cooling was provided by selective head cooling and mild systemic cooling. Death or severe disability occurred in 66% of infants randomized to conventional care and 55% randomized to the cooled group (odds ratio [OR] 0.61, 95% confidence interval [CI] 0.34 to 1.09, Pϭ0.10). The effect of head cooling for infants who had the most severe aEEG changes was not protective, but the effect of head cooling for infants who had less severe aEEG changes (nϭ172) was protective (OR 0.42, 95% CI 0.22 to 0.80, Pϭ0.009).
The large randomized, controlled pilot study performed at seven centers of 65 infants involved moderate systemic whole body hypothermia to 33.0°C for 48 hours compared with normothermia maintained at 37.0°C. (38) The safety report of this pilot study documented that infants in the hypothermia group had more significant bradycardia, longer dependence on pressor medications, higher prothrombin times, more seizures, and need for more plasma and platelet transfusions. At 12 months of age, death or severe motor scores were documented in 52% of the hypothermia group compared with 84% of the normothermia group (Pϭ0.02). In a subgroup analysis, outborn infants were more likely to die than inborn infants (OR 10.7, 95% CI 1.3 to 90.0).
The National Institute of Child Health and Human Development (NICHD) Neonatal Research Network trial of whole-body hypothermia for infants who had moderate and severe encephalopathy (in three of six categories in Table 3 ) randomized 102 infants to hypothermia to 33.5°C for 72 hours and 106 control infants to conventional care. (39) The primary outcome was death or moderate/severe disability at 18 months of age. The infants in the hypothermia group had significantly lower heart rates than the infants in the control group throughout the 72-hour intervention period. There was no significant difference in systolic or diastolic blood pressure between groups. The frequency of adverse events during study intervention was low: one infant in each group had arrhythmia, two infants in the hypothermia group had acidosis, three infants in the hypothermia group and two control group infants had bleeding, and four cooled infants had altered skin integrity. The primary outcome was noted in 44% of infants in the hypothermia group compared with 62% of infants in the control group, with a risk ratio of 0.72 (0.54 to 0.95). There was a trend for cooling to benefit infants in both moderate and severe encephalopathy groups.
The Cool Cap and the NICHD Whole Body Hypothermia Trial used different entry criteria, distinguished primarily by the use of the aEEG in the Cool Cap trial. The mode of cooling used in each trial was different, and it is not known if one cooling regimen is superior to the other. The primary outcomes were not defined in a similar manner in the two trials. Although not powered to evaluate moderate or severe encephalopathy separately, decreases in death and moderate/severe disability were seen in the whole body cooling trial in both the moderate and severe encephalopathy groups. The primary outcome of each trial was the combined end point of death or disability; hypothermia therapy did not salvage infants who had severe disabilities and would have died in the absence of the intervention. The rate of disabling cerebral palsy was reduced from 31% in the control group to 18% in the Cool Cap Study and from 30% in the control to 19% in the whole-body cooling trial of the NICHD Network.
Elevated Temperatures in Infants Who Have HIE
The NICHD trial of whole-body hypothermia demonstrated the occurrence of elevated core body temperature in the control group infants when temperatures were measured consistently in the 76 hours of study intervention and rewarming phase. (39) Of the 102 infants randomized to the usual care group, 28 had a median esophageal temperature of at least 38.0°C. Higher core temperatures were associated with significant increases in risk of death or impairment in the control group. (40) In a secondary analysis of the Cool Cap trial, investigators also noted an association between elevated temperatures in the control group and increased risk of death or disability. (41) Hyperthermia after brain injury adds to the risk of more severe neurologic damage, and studies in adults consistently support the association between higher core temperatures and worse outcome. (42) In the animal model, seizures associated with a hypoxicischemic insult result in neuronal cell death, specifically within the hippocampus. (43) The damage to the hippocampus occurs in the setting of spontaneously occurring hyperthermia of 1.5°C above normothermia; rat pups in whom hyperthermia was prevented during seizures displayed significant reductions in brain damage compared with controls. In another study, neonatal rats subjected to hypoxic-ischemic injury had selective and long-lasting learning and memory impairments during behavioral tasks, and hypothermia to 27.0°C significantly reduced the attentional deficit in behavioral tasks, whereas hyperthermia aggravated the behavioral deficit and the brain injury. (44) Four secondary analyses have been published from the NICHD randomized, controlled trial. In one study examining the relationship of elevated temperature after HIE, 22% of esophageal core temperatures measured among the control group infants were higher than 37.5°C. (40) The odds of death or disability were increased 3.6-to 4-fold for each centigrade increase in the highest quartile of temperature in the control group. Another study evaluating predictors of outcome revealed that the classification and regression tree model, rather than the scoring system developed from identified variables and odds ratios, was superior to the early neurologic examination in predicting death/disability in this study. (45) A secondary study involving spot urine samples collected in 58 study participants revealed that a high urinary lactate-to-creatinine ratio was associated with death/disability. (46) Lastly, detailed analysis of the randomized, controlled trial data revealed the safety of hypothermia during the study intervention period, the entire hospital course, and follow-up to 18 to 22 months. (47) 
Meta-analyses of Trials
Three independent systematic reviews have concluded that therapeutic hypothermia significantly reduces both death and disability after perinatal encephalopathy and is safe and that outcomes are homogeneous both within and between trials. (Table 4) . (48) 
Gaps in Knowledge
All of the current published trials have evaluated hypothermia as a neuroprotective strategy with the primary outcome of death or disability at 18 months of age. To assess efficacy in childhood, assessments of school-age outcome are being evaluated in the Cool Cap and NICHD Network Trial. The role of cranial imaging in predicting outcome among infants undergoing hypothermia is being evaluated from magnetic resonance imaging studies obtained in the NICHD trial. The role of initiating hypothermia beyond 6 hours of age in term infants is being examined because evidence suggests that effects of brain injury following hypoxia-ischemia in the preclinical model continues beyond the 6-hour therapeutic window. Hypothermia as neuroprotection for the 34 to 36-weeks' gestation neonate who has encephalopathy also is being investigated. The impact of hypothermia initiated during transport at less than 6 hours of age has not been demonstrated. The results of current whole-body cooling trials are pending. The optimum depth and duration of cooling for demonstrating greater neuroprotection is unknown. The role of pharmacologic agents used in conjunction with hypothermia as neuroprotection for hypoxic-ischemic brain injury is being investigated in preclinical studies. Of note, disability is high with severe HIE in spite of therapeutic hypothermia (Table 5) . 
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